An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)

PHASE2CompletedINTERVENTIONAL
Enrollment

117

Participants

Timeline

Start Date

March 18, 2016

Primary Completion Date

January 17, 2018

Study Completion Date

October 21, 2021

Conditions
Multiple Myeloma
Interventions
DRUG

Elotuzumab

DRUG

Pomalidomide

DRUG

Dexamethasone

Trial Locations (55)

4101

Local Institution, South Brisbane

10126

Azienda Ospedaliera Citta' Della Salute E Della Scienza Di Torino, Torino

11527

Laiko University Hospital, Athens

11528

Alexandra General Hospital Of Athens, Athens

14621

Rochester General Hospital, Rochester

15240

Va Pittsburgh Healthcare System, Pittsburgh

24105

Local Institution - 0056, Kiel

28041

Local Institution - 0024, Madrid

28204

Carolinas Healthcare System, Charlotte

29607

St Francis Hospital, Greenville

30322

Winship Cancer Institute, Atlanta

31008

Local Institution, Pamplona

33604

Local Institution - 0020, Pessac

37909

Tennessee Cancer Specialists, Knoxville

40138

A. O. U. Di Bologna, Policlinico S. Orsola Malpighi, Bologna

44000

Local Institution - 0022, Nantes

46017

Local Institution, Valencia

46260

Investigative Clinical Research Of Indiana, Llc, Indianapolis

50134

Azienda Ospedaliera Universitaria Careggi, Florence

55101

Klinikum Der Johannes Gutenberg Universitaet Mainz, Mainz

59075

St. Barbara-Klinik, Hamm

60126

Azienda Ospedaliero Universitaria Ospedali Riuniti Di Ancona, Ancona

60612

Rush University Medical Center, Chicago

69120

Local Institution - 0041, Heidelberg

72076

Universitaetsklinikum Tuebingen, Tübingen

75571

Local Institution - 0021, Paris

79106

Universitaetsklinikum Freiburg, Freiburg im Breisgau

84403

Northern Utah Associates, Ogden

86021

Local Institution - 0019, Poitiers

97448

Local Institution, Saint-Pierre

98109

University Of Washington, Seattle

1508935

Local Institution - 0027, Shibuya-ku

1900014

Local Institution - 0028, Tachikawa-shi

3091793

Local Institution - 0067, Kasama-shi

4678602

Local Institution - 0030, Nagoya

6028566

Local Institution - 0031, Kyoto

02215

Beth Israel Comprehensive Cancer Center, Boston

Dana Farber Cancer Institute., Boston

N6A 4G5

Local Institution, London

J8P 7H2

CISSS de l'Outaouais, Gatineau

H1T 2M4

Local Institution - 0048, Montreal

01307

Universitaetsklinikum Carl Gustav Carus, Dresden

00144

Local Institution, Roma

00161

Universita' La Sapienza, Roma

0208505

Local Institution - 0069, Morioka

951-8566

Local Institution - 0029, Niigata

701-1154

Local Institution - 0032, Okayama

1081 HV

Local Institution, Amsterdam

9713 GZ

Local Institution, Groningen

6229 HX

Local Institution, Maastrict

3584 CX

Local Institution, Utrecht

41-500

Oddzial Kliniczny Hematologii i Profilaktyki Chorob Nowotworowych, Chorzów

20-090

Local Institution, Lublin

60-569

Oddzial Hematologii i Transplantacji Szpiku, Poznan

08025

Local Institution, Barcelona

Sponsors

Collaborators (2)

All Listed Sponsors
collaborator

Celgene

INDUSTRY

collaborator

AbbVie

INDUSTRY

lead

Bristol-Myers Squibb

INDUSTRY